Casdin Capital

Casdin Capital is a New York-based hedge fund and crossover investor with a sharp life-sciences thesis, deploying capital across public and private healthcare and life-sciences companies. Founded by Eli Casdin, the firm has built a reputation as one of the most knowledgeable life-sciences crossover investors, with an explicit interest in genomics, diagnostics, drug discovery, biotech tools, and digital health platforms that enable next-generation medicine. For healthcare AI founders, Casdin is the right partner if your company sits at the intersection of AI and life sciences — AI-driven drug discovery, multi-omics platforms, computational biology, or diagnostics with a strong scientific and commercial narrative — and you are at Series B or later, often pre-IPO. Check sizes are plausibly $10M to $50M-plus, with capacity to participate in late-stage primary and crossover rounds and continue holding through public listing. Stage focus is growth-stage through public markets. Founders who should approach: science-credentialed founders building category-defining life-sciences platforms, with at-scale revenue or proven scientific milestones, who want a sophisticated public-private investor that can support the journey to IPO and beyond. Founders who should not approach: seed and Series A teams, pure software digital health without a life-sciences dimension, and any company that lacks the technical and commercial depth Casdin’s diligence demands. Entry path is warm introduction through tier-one biotech VCs, healthcare investment banks, or scientific KOLs in Casdin’s network. Their LinkedIn and Crunchbase pages list portfolio companies; the diligence bar is high. Be ready to be challenged on science, commercial strategy, and capital markets positioning simultaneously.